Family Medicine pp 1050-1055 | Cite as

Selected Disorders of the Skin

  • Aubrey L. Knight

Abstract

Vitiligo is an acquired loss of pigmentation and the most common cause of hypopigmentation. Histologically, the disorder is characterized by a lack of melanocytes in the epidermis. The pigment loss can be diffuse or localized. The incidence peaks between the ages of 10 and 30. The etiology of vitiligo is unknown, but it may be an autoimmune disorder with antibodies to melanocytes. There is a positive family history in 30% of cases. Vitiligo is thought to be more prevalent in dark-skinned individuals, but this may be due to easier recognition of the skin manifestations in dark-skinned persons. Vitiligo is associated with thyroid disorders in up to 30% of cases, and there are reported associations with alopecia areata, pernicious anemia, other autoimmune and endocrine disorders, and melanoma.

Keywords

Hair Loss Lichen Planus Alopecia Areata Nail Plate Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Habif TP. Clinical dermatology: a color guide to diagnosis and therapy. 3rd ed. St. Louis: Mosby, 1996:211–27.Google Scholar
  2. 2.
    Potter B. Hydroxychloroquine. Cutis 1993;52:229–31.PubMedGoogle Scholar
  3. 3.
    Brainard BJ. Managing corns and plantar calluses. Phys Sportsmed 1991;19:61–7.Google Scholar
  4. 4.
    Habif TP. Clinical dermatology: a color guide to diagnosis and therapy. 3rd ed. St. Louis: Mosby, 1996:765–9.Google Scholar
  5. 5.
    Zaias N. Onychomycosis. Arch Dermatol 1972;105:263–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Körting HC, Schafer-Korting M, Zienicke H, Georgii A, Ollert MW. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37:2064–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992;304:1151–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Der Schroeff JG, Cirkel PKS, Van Dijk TJA, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126:36–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Nahass GT, Sisto M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993;186:59–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Zaias N, Drachman D. A method for the determination of drug effectiveness in onychomycosis: trials with ketocon-azole and griseofulvin ultramicrosize. J Am Acad Dermatol 1983;9:912–19.PubMedCrossRefGoogle Scholar
  11. 11.
    Ruoff AC. Foot and ankle. In: Wolcott MW, editor. Ambulatory surgery. Philadelphia: Lippincott, 1988.Google Scholar
  12. 12.
    Hefland AE. Nail and hyperkeratotic problems in the elderly foot. Am Fam Physician 1989;39:101–10.Google Scholar
  13. 13.
    Atton AV, Tunnessen WW. Alopecia in children: the most common causes. Pediatr Rev 1990;12:25–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Burke KE. Hair loss: what causes it and what can be done about it? Postgrad Med 1989;85:52–77.PubMedGoogle Scholar
  15. 15.
    Caserio RJ, Hordinsky MK. Disorders of hair. J Am Acad Dermatol 1988;19:895–903.PubMedCrossRefGoogle Scholar
  16. 16.
    DeVillez RL. Topical minoxidil therapy in hereditary androgenic alopecia. Arch Dermatol 1985;121:197–202.CrossRefGoogle Scholar
  17. 17.
    Olsen EA, Weiner MS, DeLong ER, Pinnell S. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985;13:185–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Olsen EA, DeLong ER, Weiner MS: Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol 1986;15:30–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Price VH, Menefee E. Quantitative estimation of hair growth. I. Androgenic alopecia in women: effect of minoxidil. J Invest Dermatol 1990;95:683–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Olsen EA, Weiner MS. Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. J Am Acad Dermatol 1987;17:97–101.PubMedCrossRefGoogle Scholar
  21. 21.
    Franz TF. Percutaneous absorption of minoxidil in man. Arch Dermatol 1985;121:203–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Aubrey L. Knight

There are no affiliations available

Personalised recommendations